United States - English - NLM (National Library of Medicine)

avkare, inc. - levomefolate calcium (unii: a9r10k3f2f) (levomefolic acid - unii:8s95dh25xc), methylcobalamin (unii: br1sn1js2w) (methylcobalamin - unii:br1sn1js2w), acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - levomefolate calcium 6 mg - l-methyl-mc-nac tablets is indicated for the distinct nutritional requirements of individuals under a physician's treatment for early memory loss 25 with particular emphasis for those individuals diagnosed with or at risk for neurovascular oxidative stress 14,16,18 and/or hyperhomocysteinemia 18 ; mild to moderate cognitive impairment with or without vitamin b12 deficiency 9,13,19 , vascular dementia 12,13,21 or alzheimer's disease 12,13,16,21 . l-methyl-mc-nac tablets should always be used under medical supervision. there have been rare reports of hypersensitivity (allergic-like reactions) to l-methyl-mc-nac tablets. therefore, a known hypersensitivity to any components in the product is a contraindication to its use for any indication.

United States - English - NLM (National Library of Medicine)

jacobus pharmaceutical company, inc. - aminosalicylic acid (unii: 5b2658e0n2) (aminosalicylic acid - unii:5b2658e0n2) - aminosalicylic acid 4 g - paser is indicated for the treatment of tuberculosis in combination with other active agents. it is most commonly used in patients with multi-drug resistant tb (mdr-tb) or in situations when therapy with isoniazid and rifampin is not possible due to a combination of resistance and/or intolerance. when paser is added to the treatment regimen in patients proven or suspected drug resistance, it should be accompanied by at least one and preferably two other new agents to which the patient's organism is known or expected to be susceptible. hypersensitivity to any component of this medication. severe renal disease. patients with severe renal disease will accumulate aminosalicylic acid and its acetyl metabolite but will continue to acetylate, thus leading exclusively to the inactive acetylated form; deacetylation, if any, is not significant. the half life of free aminosalicylic acid in renal disease is 30.8 minutes in comparison to 26.4 minutes in normal volunteers. but the half life of the inactive metabolite is 30